Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 20Recruiting 10Unknown 7Terminated 4Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 7Tumor-Agnostic 5Thoracic 5Genitourinary 4Head & Neck 2Dermatologic 2Sarcoma 1Other hematologic neoplasm 1Classical hematology 1CNS 1Breast 1

Conditions

Breast Neoplasms 544Triple Negative Breast Neoplasms 87Neoplasms 19Colorectal Neoplasms 19Lung Neoplasms 16Advanced Breast Cancer 16Neoplasm Metastasis 15Carcinoma, Non-Small-Cell Lung 15Prostatic Neoplasms 14Motor Activity 12Breast Cancer Lymphedema 12HER2-positive Breast Cancer 11Uterine Cervical Neoplasms 10Stomach Neoplasms 10Ovarian Neoplasms 10Carcinoma, Intraductal, Noninfiltrating 10Anxiety Disorders 10Endometrial Neoplasms 9Depression 8Brain Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Pain, Postoperative 6Pain 6Melanoma 6Lymphedema 6Head and Neck Neoplasms 6Colonic Neoplasms 6Cardiotoxicity 6Sarcoma 5Pancreatic Neoplasms 5

Interventions

pemigatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma × Breast × Clear all
NCT06551896 2024-08-13

Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Not yet recruiting
30 enrolled
BreastGastrointestinalGenitourinarySarcomaThoracic

Breast Neoplasms, Carcinoma, Carcinoma, Transitional Cell, Lung Neoplasms, Sarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡